ESSA Pharma Inc
EPIX1.880USD
0.000
Market hours （ET）Quotes delayed by 15 min
83.45MMarket Cap
LossP/E TTM
More Details of ESSA Pharma Inc Company
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Company Info
Ticker SymbolEPIX
Company nameESSA Pharma Inc
IPO dateFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Number of employees35
Security typeOrdinary Share
Fiscal year-endFeb 22
Address999 West Broadway, Suite 720
CityVANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV5Z 1K5
Phone17783310962
Websitehttps://www.essapharma.com/
Ticker SymbolEPIX
IPO dateFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Alex Martin
Mr. Alex Martin
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Shareholder Types
Shareholders
Proportion
Hedge Fund
46.19%
Investment Advisor
13.36%
Research Firm
11.99%
Corporation
3.77%
Investment Advisor/Hedge Fund
2.45%
Individual Investor
2.24%
Venture Capital
0.05%
Other
19.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
91
33.44M
75.34%
-17.34M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
2023Q1
185
36.21M
82.14%
-19.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
8.75M
19.71%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.26M
5.1%
--
--
Apr 23, 2025
Tang Capital Management, LLC
4.30M
9.69%
--
--
Mar 31, 2025
BML Capital Management LLC
4.22M
9.51%
--
--
Apr 24, 2025
Morgan Stanley & Co. LLC
4.20M
9.46%
+10.76K
+0.26%
Mar 31, 2025
Opaleye Management Inc.
2.21M
4.98%
--
--
Mar 31, 2025
Pfizer Inc
1.68M
3.77%
--
--
Mar 31, 2025
Altium Capital Management LP
1.05M
2.37%
-377.63K
-26.44%
Mar 31, 2025
Berger (Franklin Milan)
784.40K
1.77%
--
--
Jan 08, 2025
BofA Global Research (US)
698.27K
1.57%
-114.04K
-14.04%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
